- Home
- PRME vs ABUS Comparison
PRME vs ABUS Comparison
Compare PRME & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- ABUS
- Stock Information
- Founded
- PRME 2019
- ABUS N/A
- Country
- PRME United States
- ABUS United States
- Employees
- PRME N/A
- ABUS N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- ABUS Health Care
- Exchange
- PRME Nasdaq
- ABUS Nasdaq
- Market Cap
- PRME 588.2M
- ABUS 772.1M
- IPO Year
- PRME 2022
- ABUS N/A
- Fundamental
- Price
- PRME $3.55
- ABUS $4.55
- Analyst Decision
- PRME Strong Buy
- ABUS Strong Buy
- Analyst Count
- PRME 9
- ABUS 3
- Target Price
- PRME $14.75
- ABUS $4.67
- AVG Volume (30 Days)
- PRME 524.5K
- ABUS 1.1M
- Earning Date
- PRME 11-01-2024
- ABUS 11-05-2024
- Dividend Yield
- PRME N/A
- ABUS N/A
- EPS Growth
- PRME N/A
- ABUS N/A
- EPS
- PRME N/A
- ABUS N/A
- Revenue
- PRME $591,000.00
- ABUS $10,061,000.00
- Revenue This Year
- PRME N/A
- ABUS N/A
- Revenue Next Year
- PRME N/A
- ABUS N/A
- P/E Ratio
- PRME N/A
- ABUS N/A
- Revenue Growth
- PRME N/A
- ABUS N/A
- 52 Week Low
- PRME $3.47
- ABUS $1.69
- 52 Week High
- PRME $13.27
- ABUS $4.56
- Technical
- Relative Strength Index (RSI)
- PRME 31.37
- ABUS 80.58
- Support Level
- PRME $4.17
- ABUS $3.79
- Resistance Level
- PRME $4.40
- ABUS $3.92
- Average True Range (ATR)
- PRME 0.30
- ABUS 0.14
- MACD
- PRME -0.03
- ABUS 0.07
- Stochastic Oscillator
- PRME 6.67
- ABUS 98.86
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.